Dean Bornilla, Pace® Life Sciences, highlights his organization's future role in supporting biopharmaceutical development and manufacturing coast-to-coast.
Pace® Life Sciences, a biopharmaceutical services provider, has experienced significant growth through recent acquisitions of analytical labs, substantially increasing their testing capacity and scientific expertise. Looking ahead to 2025, Pace® is undertaking key expansions at their Salem, NH, site to include sterile fill-finish capabilities for clinical trial manufacturing and at their Oakdale, MN, facility to double their biopharmaceutical analytical services. With a growing network of locations across major US pharmaceutical hubs, Pace® aims to enhance customer experience through consistent quality and timely delivery. The company anticipates continued growth through both organic initiatives and further acquisitions, supported by private equity investment.
Watch this video and learn more about:
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.